drugset / Trial / NCT00199875
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Phase 1
Completed
18 enrolled
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250 (\^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma (RCC). Study objectives were to determine the safety, targeting, and dosimetry of \^90Y-DOTA-cG250, using indium-111 conjugated chimeric G250 (\^111In-DOTA-cG250) as a surrogate, as well as to evaluate the immunogenicity of cG250.
Timeline
- Start
- 2005-07-06
- Primary completion
- 2013-03-14
- Completion
- 2013-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ^90Y-DOTA-cG250 | Monoclonal antibody | 7.4 mbq/kg | Intravenous |
| Subject | ^90Y-DOTA-cG250 | Monoclonal antibody | 11.1 mbq/kg | Intravenous |
| Subject | ^90Y-DOTA-cG250 | Monoclonal antibody | 14.8 mbq/kg | Intravenous |
| Subject | ^90Y-DOTA-cG250 | Monoclonal antibody | 16.65 mbq/kg | Intravenous |
| Subject | ^90Y-DOTA-cG250 | Monoclonal antibody | 20.35 mbq/kg | Intravenous |